Kario et al. [25] reported that CAVI reduction was not observed after 24 weeks of treatment with either of two xanthine oxidase inhibitors, topiroxostat or febuxostat, in hypertensive patients with hyperuricemia in the BEYOND UA study. The gene discussed is XDH; the disease is hyperuricemia.